Celator Pharmaceuticals, Inc. today announced that VYXEOS™ (formerly referred to as CPX-351) was recognized with the Nanomedicine Award 2015. This award recognizes projects or products that have been developed using innovative solutions based on nanotechnology.
Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University developing novel nanotherapeutics for clearing obstructed blood vessels have teamed up with researchers at University of Massachusetts' New England Center for Stroke Research (NECSTR) to develop a new, highly effective drug-device combination for treating life-threatening blood clots in patients with stroke.
BIND Therapeutics, Inc., a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, today announced that four abstracts have been accepted for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held in Boston, November 5-9, 2015.
Senior Scientific, LLC, a unit of Manhattan Scientifics and a developer of nanobiotechnology for the early detection and localization of cancer and other human diseases, today announced that the Company has recently been granted a patent by the Chinese Patent Office, Patent No. CN102695473 A, covering the "Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof."
A nanofiber hydrogel infused with snake venom may be the best material to stop bleeding quickly, according to Rice University scientists.
An overview of the range of useful applications of halloysite clay tubes has been published. The naturally occuring, biocompatible, nanoscale tubes can be used for sustained drug delivery and alongside enzymes as biocatalytic nanoreactors.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it has been selected as a Cavendish Innovation Partner and will present at the Cavendish Global Health Impact Forum co-hosted by The Cleveland Clinic, which takes place October 25th to October 28th at The Cleveland Clinic, Cleveland, Ohio.
Novavax, Inc., a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun in a Phase 2 rollover clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Vaccine) in older adults enrolled in the prior Phase 2 trial.
A team of researchers at the UCLA School of Dentistry has discovered that nanodiamonds can effectively strengthen a material used for filling teeth during root canal procedures, and can prevent residual infection post treatment.
Protease inhibitors are a class of antiviral drugs that are commonly used to treat HIV, the virus that causes AIDS. Scientists at the University of Nebraska Medical Center designed a new delivery system for these drugs that, when coupled with a drug developed at the University of Rochester School of Medicine and Dentistry, rid immune cells of HIV and kept the virus in check for long periods. The results appear in the journal Nanomedicine: Nanotechnology, Biology and Medicine.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.